AOP Orphan Strengthens Core CNS Specialty Business with High Promise in Movement Disorder Treatments
Vienna, Austria, June 19, 2015 / B3C newswire / -- AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK …